查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887170

镥-177 (Lu-177) 市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測 (2024-2032)

Lutetium-177 Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

镥-177 (Lu-177) 市場成長驅動因子

隨著標靶放射性核種療法在癌症治療中日益重要，全球镥-177 (Lu-177) 市場正在快速擴張。根據最新評估，預計2024年市場規模將達到21.5億美元，2025年達到27.3億美元，到2032年將達到108.4億美元。這意味著2025年至2032年的複合年增長率（CAGR）為21.8%。這一快速增長主要受癌症發病率上升、標靶治療的日益普及以及新一代Lu-177放射性藥物供應量增加的推動。

市場概覽

镥-177是一種β射線放射性同位素，用於標靶放射性核種治療，特別適用於神經內分泌腫瘤（NETs）和攝護腺癌，這兩種腫瘤的發生率在全球範圍內均呈上升趨勢。镥-177能夠特異性地與腫瘤受體結合，例如NETs中的生長抑素受體和前列腺癌中的PSMA（前列腺特異性抗原受體），從而實現將輻射精準地輸送到癌細胞，同時保護健康組織。主要市場參與者包括諾華製藥（Novartis AG）、蘭特斯控股公司（Lantheus Holdings, Inc.）、泰利克斯製藥公司（Telix Pharmaceuticals, Inc.）和雷迪製藥診斷公司（Radiopharm Theranostics, Inc.），這些公司都在積極拓展其镥-177 (Lu-177)。

全球精準腫瘤學的興起也推動了市場發展，放射性配體療法 (RLT) 已成為傳統療法無效患者的重要治療選擇。

主要地區市場規模及趨勢

2024年，北美在全球市場佔主導地位，市佔率高達82.79%。這主要得益於該地區較高的癌症發生率、完善的醫保報銷系統以及先進的放射性藥物生產設施。預計到 2024 年，該地區的收入將達到 17.8 億美元，其中美國憑藉 SHINE Technologies 位於簡斯維爾的 Lu-177 工廠（北美最大的 Lu-177 工廠）等關鍵設施，引領著生產市場。

歐洲在 2024 年佔第二大市場佔有率，這得益於其強大的臨床基礎設施和標靶療法的日益普及。英國薩頓核醫治療中心的啟用進一步增強了該地區提供 Lu-177 PSMA 療法的能力。

亞太地區預計將成為成長最快的地區，這主要得益於癌症病例的增加、臨床試驗的擴展以及各項合作計畫的支持。 Radiopharm Theranostics 與 ANSTO 達成協議，供應未摻雜的釕-177，這凸顯了對先進放射性藥物的持續投資。

市場驅動因素

1.癌症發生率上升

前列腺癌、神經內分泌腫瘤和其他惡性腫瘤的發生率不斷上升是推動市場成長的關鍵因素。僅在美國，預計到 2025 年將新增 313,780 例前列腺癌病例。镥-177 能夠靶向輸送 β 射線，使其成為晚期和難治性癌症的首選治療方法。

2. 標靶治療需求不斷成長

標靶放射性核素治療可減少副作用並改善治療效果。 Lutathera（釕-177 多肽）和 Plavicto（釕-177 維匹博肽四環素）等產品的日益普及持續推動著市場成長。

市場限制因子

高額的治療費用限制了中低收入國家的採用。單次注射 Pluvicto 的價格根據地區不同，從 5,000 美元到 12,000 美元不等，平均療程需要六次注射。放射治療基礎設施的匱乏和不完善的報銷體系進一步阻礙了其在全球的推廣應用。

市場機會

推進臨床研究帶來了巨大的機會。在髓母細胞瘤、乳癌、膠質母細胞瘤和非小細胞肺癌 (NSCLC) 領域，使用鎔-177 進行的臨床試驗數量不斷增加，這正在擴大治療範圍。諸如 177Lu-omburtamab-DTPA 獲得 RPDD（監管優先開發認定）等批准，正在拓展兒科腫瘤領域的治療選擇。

市場趨勢

聯合療法

將釕-177與免疫療法、DNA修復抑制劑和化療合併應用正成為一大趨勢。 Telix Pharmaceuticals 的 STARSTRUCK I 期臨床試驗（TLX250 與 peposertib 合併用藥）代表治療方案向協同增效方向的轉變。

細分市場洞察

依藥物分類

  • 由於神經內分泌腫瘤發生率的上升，Lutathera 在 2024 年佔了市場主導地位。
  • 受前列腺癌治療需求旺盛以及加拿大和歐洲醫保報銷政策改善的推動，PLUVICTO 正在快速擴張。

依年齡組

  • 2024年，由於65歲及以上男性前列腺癌的高發生率，成人佔了最大的市場佔有率。
  • 隨著美國食品藥物管理局（FDA）批准镥-177療法用於12歲以上患者，兒科市場預計將快速成長。

依應用領域

  • 2024年，由於核准療法數量不斷增加以及治療方案的廣泛應用，前列腺癌市場佔主導地位。
  • 由於臨床研發的不斷拓展，神經內分泌腫瘤預計將實現強勁成長。

依最終使用者

  • 2024年，在專業核醫基礎設施的推動下，醫院市場佔主導地位。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家和地區主要疾病盛行率（2024 年）
  • 主要公司產品線分析
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）
  • 新冠疫情對市場的影響

第五章：全球镥市場177 市場分析、洞察與預測 (2019-2032)

  • 市場分析、洞察與預測 - 依藥物類型劃分
    • Lutathera（镥-177 多他特）
    • Pruvict（镥-177 維匹博肽四氫西坦）
    • 其他
  • 市場分析、洞察與預測 - 依年齡組別劃分
    • 成人
    • 兒科
  • 市場分析、洞察與預測 - 依應用領域劃分
    • 神經內分泌腫瘤
    • 攝護腺癌
    • 其他
  • 市場分析、洞察與預測 - 依最終用戶劃分
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 世界其他地區

第六章：北美鎧-177市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲镥-177市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區镥-177市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：世界其他地區镥-177市場分析、洞察與預測（2019-2032）

第十章：競爭分析

  • 全球市佔率分析（2024）
  • 公司型材
    • 諾華公司
    • 泰利克斯製藥股份有限公司
    • Ariceum 療法
    • Radiopharm Theranostics 有限公司
    • Lantheus 控股公司
    • Y-mAbs Therapeutics, Inc.
    • 格萊泰瑞克斯
    • 銼
Product Code: FBI112740

Growth Factors of Lutetium-177 (Lu-177) Market

The global Lutetium-177 (Lu-177) market is experiencing rapid expansion as targeted radionuclide therapy gains global prominence in cancer treatment. According to the latest assessment, the market was valued at USD 2.15 billion in 2024, is projected to rise to USD 2.73 billion in 2025, and is expected to reach USD 10.84 billion by 2032, registering a strong CAGR of 21.8% during 2025-2032. This accelerated growth is driven by increasing cancer prevalence, expanding adoption of targeted therapies, and the growing availability of next-generation Lu-177 radiopharmaceuticals.

Market Overview

Lutetium-177 is a beta-emitting radioisotope used in targeted radionuclide therapy, particularly for neuroendocrine tumors (NETs) and prostate cancer, two cancer types with rising global incidence. Its unique ability to bind to tumor receptors-such as somatostatin receptors in NETs and PSMA in prostate cancer-allows precise delivery of radiation directly to cancer cells while preserving healthy tissues. Key market players include Novartis AG, Lantheus Holdings, Inc., Telix Pharmaceuticals, and Radiopharm Theranostics, all actively expanding their Lu-177 portfolios and production capabilities.

The market is also supported by the global shift toward precision oncology, where radioligand therapy (RLT) is emerging as a vital treatment option for patients who fail conventional therapies.

Market Size & Key Regional Insights

North America dominated the global market in 2024, holding a substantial 82.79% share, driven by high cancer prevalence, strong reimbursement frameworks, and the presence of advanced radiopharmaceutical manufacturing facilities. Regional revenue reached USD 1.78 billion in 2024, with the U.S. leading production due to major facilities like SHINE Technologies' Lu-177 plant in Janesville, the largest in North America.

Europe accounted for the second-largest market share in 2024, supported by robust clinical infrastructure and rising adoption of targeted therapies. The launch of the Nuclear Medicine Therapy Centre in Sutton, U.K., further strengthened the region's capabilities in administering Lu-177 PSMA therapy.

Asia Pacific is projected to be the fastest-growing region, driven by rising cancer cases, expanding clinical trials, and supportive collaboration initiatives. Partnerships such as Radiopharm Theranostics' agreement with ANSTO to supply non-carrier-added Lu-177 highlight ongoing investments in advanced radiopharmaceuticals.

Market Drivers

1. Rising Cancer Prevalence

The increasing incidence of prostate cancer, neuroendocrine tumors, and other malignancies is a primary growth driver. In the U.S. alone, 313,780 new prostate cancer cases are estimated for 2025. Lu-177's ability to deliver targeted beta radiation makes it a preferred therapy for advanced and treatment-resistant cancers.

2. Growing Demand for Targeted Treatment

Targeted radionuclide therapy reduces side effects and improves treatment outcomes. Increasing adoption of products like LUTATHERA (Lu-177 dotatate) and PLUVICTO (Lu-177 vipivotide tetraxetan) continues to fuel market expansion.

Market Restraints

High treatment costs restrict adoption in lower-middle-income countries. A single dose of Pluvicto can cost USD 5,000-12,000 depending on the region, with an average treatment regimen requiring six doses. Limited radiotherapy infrastructure and insufficient reimbursement policies further challenge global adoption.

Market Opportunities

Growing clinical research presents significant opportunities. Increasing numbers of clinical trials on Lu-177 for medulloblastoma, breast cancer, glioblastoma, and NSCLC are widening the therapeutic scope. Regulatory approvals-such as the RPDD for 177Lu-omburtamab-DTPA-are expanding treatment options into pediatric oncology.

Market Trends

Combination Therapy Integration

Combining Lu-177 with immunotherapy, DNA-repair inhibitors, and chemotherapy is emerging as a key trend. Telix Pharmaceuticals' STARSTRUCK Phase I trial combining TLX250 with peposertib exemplifies this shift toward synergistic treatment options.

Segmentation Insights

By Drug

  • LUTATHERA dominated in 2024 due to rising neuroendocrine tumor incidence.
  • PLUVICTO is expanding rapidly, driven by high demand for prostate cancer therapeutics and improving reimbursement access in Canada and Europe.

By Age Group

  • Adults held the largest share in 2024 due to high prostate cancer prevalence among men aged 65+.
  • Pediatrics is expected to grow rapidly following FDA approvals for Lu-177 therapies in children aged 12+.

By Application

  • Prostate cancer led the market in 2024 due to increased approvals and treatment availability.
  • Neuroendocrine tumors expected strong growth driven by expanding clinical development.

By End-User

  • Hospitals dominated the market in 2024 due to specialized nuclear medicine infrastructure.

Conclusion

With its market value rising from USD 2.15 billion in 2024 to USD 10.84 billion by 2032, the Lutetium-177 market is poised for transformational growth. Increasing cancer incidence, expanding radioligand therapy approvals, and strong regional production capabilities position Lu-177 as a cornerstone in the future of precision oncology.

Segmentation By Drug

  • LUTATHERA (lutetium Lu 177 dotatate)
  • PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • Others

By Age Group

  • Adults
  • Pediatrics

By Application

  • Neuroendocrine Tumor
  • Prostate Cancer
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America (By Drug, Age Group, Application, End-User, and Country)
    • U.S.
    • Canada
  • Europe ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World ( By Drug, Age Group, Application, and End-User)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 5.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Adults
    • 5.2.2. Pediatrics
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Neuroendocrine Tumors
    • 5.3.2. Prostate Cancer
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-User
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Clinics
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 6.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Adults
    • 6.2.2. Pediatrics
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Neuroendocrine Tumors
    • 6.3.2. Prostate Cancer
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 7.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Adults
    • 7.2.2. Pediatrics
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Neuroendocrine Tumors
    • 7.3.2. Prostate Cancer
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 8.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Adults
    • 8.2.2. Pediatrics
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Neuroendocrine Tumors
    • 8.3.2. Prostate Cancer
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-User
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Rest of the World Lutetium-177 Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 9.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Adults
    • 9.2.2. Pediatrics
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Neuroendocrine Tumors
    • 9.3.2. Prostate Cancer
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-User
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles
    • 10.2.1. Novartis AG
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Telix Pharmaceuticals Limited
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Ariceum Therapeutics
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Radiopharm Theranostics Limited
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Lantheus Holdings, Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Y-mAbs Therapeutics, Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. GLYTHERIX
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Curium
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 2: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 3: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 4: Global Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 5: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 7: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 8: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 9: North America Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 10: North America Lutetium-177 Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 12: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 13: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 14: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 15: Europe Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 17: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 18: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 19: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 20: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 22: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 23: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 24: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 25: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Lutetium-177 Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Lutetium-177 Market Value Share (%), by Drug, 2024 & 2032
  • Figure 3: Global Lutetium-177 Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 4: Global Lutetium-177 Market Value Share (%), by Application, 2024 & 2032
  • Figure 5: Global Lutetium-177 Market Value Share (%), by End-User, 2024 & 2032
  • Figure 6: North America Lutetium-177 Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 7: North America Lutetium-177 Market Value Share (%), by Drug, 2024
  • Figure 8: North America Lutetium-177 Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 9: North America Lutetium-177 Market Value Share (%), by Age Group, 2024
  • Figure 10: North America Lutetium-177 Market Value (USD billion), by Application, 2024 & 2032
  • Figure 11: North America Lutetium-177 Market Value Share (%), by Application, 2024
  • Figure 12: North America Lutetium-177 Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 13: North America Lutetium-177 Market Value Share (%), by End-User, 2024
  • Figure 14: North America Lutetium-177 Market Value (USD billion), By Country, 2024 & 2032
  • Figure 15: North America Lutetium-177 Market Value Share (%), By Country, 2024
  • Figure 16: Europe Lutetium-177 Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 17: Europe Lutetium-177 Market Value Share (%), by Drug, 2024
  • Figure 18: Europe Lutetium-177 Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 19: Europe Lutetium-177 Market Value Share (%), by Age Group, 2024
  • Figure 20: Europe Lutetium-177 Market Value (USD billion), by Application, 2024 & 2032
  • Figure 21: Europe Lutetium-177 Market Value Share (%), by Application, 2024
  • Figure 22: Europe Lutetium-177 Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 23: Europe Lutetium-177 Market Value Share (%), by End-User, 2024
  • Figure 24: Europe Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 25: Europe Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 26: Asia Pacific Lutetium-177 Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 27: Asia Pacific Lutetium-177 Market Value Share (%), by Drug, 2024
  • Figure 28: Asia Pacific Lutetium-177 Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 29: Asia Pacific Lutetium-177 Market Value Share (%), by Age Group, 2024
  • Figure 30: Asia Pacific Lutetium-177 Market Value (USD billion), by Application, 2024 & 2032
  • Figure 31: Asia Pacific Lutetium-177 Market Value Share (%), by Application, 2024
  • Figure 32: Asia Pacific Lutetium-177 Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 33: Asia Pacific Lutetium-177 Market Value Share (%), by End-User, 2024
  • Figure 34: Asia Pacific Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 35: Asia Pacific Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 36: Rest of the World Lutetium-177 Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 37: Rest of the World Lutetium-177 Market Value Share (%), by Drug, 2024
  • Figure 38: Rest of the World Lutetium-177 Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 39: Rest of the World Lutetium-177 Market Value Share (%), by Age Group, 2024
  • Figure 40: Rest of the World Lutetium-177 Market Value (USD billion), by Application, 2024 & 2032
  • Figure 41: Rest of the World Lutetium-177 Market Value Share (%), by Application, 2024
  • Figure 42: Rest of the World Lutetium-177 Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 43: Rest of the World Lutetium-177 Market Value Share (%), by End-User, 2024
  • Figure 44: Rest of the World Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Rest of the World Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2024

Figure 46: Global Lutetium-177 Market Share (%), By Company, 2024